The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

| Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

Trump recently proposed tariffs on pharmaceutical products. Experts say this could lead to added costs, drug shortages and ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...